INTRODUCTION
The proteasome represents a novel putative target for cancer therapy. PS-341 (Velcade/bortezomib) is a dipeptidyl boronic acid inhibitor with high specificity for the proteasome (1, 2) . It is currently used in the treatment of patients with multiple myeloma (3, 4, 5, 6, 7) . Preclinical studies have suggested that proteasome inhibitors show antitumour activity against solid tumours, including carcinomas of the breast (8) , lung (9) , colon (10), bladder (11) , ovary, prostate (12), pancreas (13) and glioblastoma multiforme.
Furthermore, evidence has shown that transformed cells appear to be more susceptible to proteasome inhibitorinduced apoptosis than nontransformed cells. Finally, these inhibitors can sensitize cancer cells to death induced by members of the TNF family such as TRAIL . The antitumoural effects of bortezomib have been extensively studied in multiple myeloma, being inactivation of NF-kB one of the proposed mechanisms of action. NF-kB is a pleiotropic transcription factor, which is activated by a broad variety of stimuli such as growth factors, cytokines, ionizing radiation, ultraviolet light or chemotherapeutic drugs (14, 15) NF-kB regulates the expression of a large number of genes, which carry important functions in inflammation, apoptosis, proliferation, and angiogenesis. NF-kB shows constitutive or increased activity in a wide variety of tumours (16, 17), including endometrial carcinoma (18) and plays a crucial role in neoplastic transformation (16, 19) . In resting cells, NF-kB is held inactive in the cytoplasm, bound to the inhibitors of NF-kB (IkB). Activation of the canonical NF-kB pathway depends on stimuliinduced phosphorylation of the IkB kinase (IKK) complex, which includes the kinases IKKα, IKKβ, and the regulatory subunit IKKγ. Activated IKKs induce phosphorylation of IkBα on serines 32 and 36, and the subsequent ubiquitination and degradation by a proteasomedependent pathway.
Free NF-kB is then translocated to the nucleus where it regulates the transcription of several sets of genes. Optimal activation of NF-kB transcriptional activity requires phosphorylation of NF-kB subunits such as p65. In addition, NF-kB activity can be further modulated by phosphorylation of p65 subunit. P65 sequence contains several serine residues that can be phosphorylated (20) . One of such residues is the serine 536, which can be phosphorylated by several kinases in different signalling pathways. Phosphorylation of p65 at serine 536 is accomplished by several different stimuli such as lymphotoxin beta (21) , TNF (22) , lipopolysaccharide (23) or IL-1 (24). The main goal of the present study was to demonstrate that Bortezomib and other three proteasome inhibitors induce apoptosis in endometrial carcinoma cell lines and primary culture explants obtained from endometrial carcinoma tumour samples. However, we have found that such inhibitors activate NF-kB. Proteasome inhibitors induced phosphorylation and reduction of the levels of IκBα protein and phosphorylation of p65 subunit on serine 536, leading to increased NF-kB transcriptional activity. P65 phosphorylation and IkBα degradation depended on either IKKα and IKKβ. Proteasome inhibitor-induced activation of NF-kB required degradation of IkBα, and also functional expression of IKKα, IKKβ and p65 NF-kB subunit. Proteasome inhibitors have been widely used as pharmacological inhibitors of NFkB. However, our results demonstrate that this may not always be the case. Therefore, an accurate study of the effects of proteasome inhibitors in signalling pathways may be needed in specific cell types. More importantly, our results may also have clinical relevance because proteasome inhibitors are currently used as anticancer drugs. (JP) . A specific informed consent was obtained from each patient, and the study was approved by the local Ethic Committee. Tissue was collected in DMEM, chopped in 1 mm pieces and incubated with collagenase in DMEM for 1,5 hours at 37ºC with periodic mixing. Digested tissue was mechanically dissociated through a 10 ml pipette and a 1 ml blue tip and resuspended in 2 ml of fresh DMEM medium. To separate endometrial epithelial cells from the stromal fraction, the dissociated tissue was seeded on top of 8 ml of DMEM medium and tissue was allowed to sediment by gravity for 5 minutes. This step was repeated three times. Finally, tissue explants were resuspended in DMEM supplemented with 10% Foetal Bovine Serum, 1 mM sodium pyruvate, 2 mM Lglutamine and 1% of penicilin/streptomicin (Sigma) and seeded on M24 multiwell plates. Explant cultures were incubated at 37ºC with saturating humidity and 5% CO 2 . After two days in culture, explants were treated with the indicated concentrations of proteasome inhibitors. Lentiviral production and infectionOligonucleotides to produce plasmid based shRNA were cloned into the FSFsi vector using AgeI-BamHI restriction sites. shRNA target sequence to IKKα was GCAGGCTCTTTCAGGGACA and target sequence to IKKβ was
EXPERIMENTAL PROCEDURES

AAAGTGTCAGCTGTATCCT.
To produce infective lentiviral particles, 293T cells were cotransfected by calcium phosphate method with the virion packaging elements (VSV-G and Δ8.9) and the shRNA producing vector (FSPsi) or the expression vector (FCIV) on 293T human embryonic kidney. 293T cells were allowed to produce lentiviral particles during 3-4 days in same culture medium used for endometrial cell lines and explants. Culture medium was collected, centrifuged for 5 minutes at 1000 rpm and filtered through a 0. 45 
RESULTS
Proteasome inhibitors induce cell death on endometrial adenocarcinoma cell lines.
Bortezomib is currently used as chemotherapeutic agent in patients with relapsed multiple myeloma. It is under ongoing clinical trials for evaluation of efficacy in the treatment of some solid tumours. However, some tumoural cell types undergo apoptosis or cell growth arrest after proteasome inhibitor treatment whereas others are insensitive to them, or require cotreatment with other drugs or factors. To investigate whether bortezomib and other three proteasome inhibitors were able to induce cell death on endometrial adenocarcinoma cells; we treated four endometrial carcinoma (EC) cell lines, Ishikawa (IK), KLE, RL-95 (RL) and HEC-1-A (HEC) with bortezomib and three other different proteasome inhibitors (MG-132, Epoxomicin or ALLN). All proteasome inhibitors tested caused a dose-dependent decrease on cell viability as assessed by MTT (Fig 1A, 1B) . The reduction on viability was accompanied by an increase of apoptotic nuclei as seen by Hoechst staining (Fig 1C) suggesting apoptotic cell death. Treatment with MG-132 resulted in processing of caspase-3 and caspase-9. (Fig 1D) . Co-treatment of IK with bortezomib or MG-132 plus BAF, a broad specificity caspase inhibitor almost completely abolished cell death (Fig 1E) . Altogether these data indicate that proteasome inhibitors are effective in inducing apoptotic cell death on endometrial carcinoma cell lines. Proteasome inhibitors induce phosphorylation and degradation of IkBα. Inhibition of proteasome prevents NF-kB activation and causes cell cycle arrest or cell death on many different types of cell. The antitumoural effects of bortezomib have been proposed to involve NF-kB inhibition as a main mechanism of action. To investigate whether this was the case in our cell lines, we assessed the levels of IkBα, after treatment with proteasome inhibitors. Time course treatment of IK, HEC or RL cells with 25 nM of bortezomib resulted in a marked increase on phosphorylation of serine 32, followed by reduction of IkBα protein levels over time (Fig 2A) . To rule out the possibility that IkBα phosphorylation and reduction were non-specific effects of bortezomib in our particular cell lines, we treated IK cells with the other three proteasome inhibitors. Treatment of IK cells with MG-132 resulted in phosphorylation and reduction of IkBα, similar to that observed with Bortezomib ( Fig 2B) . Although each cell line showed different basal levels of IkBα, treatment with MG-132 resulted in a similar reduction on IkBα levels in all of them ( Fig 2C) . We also observed a significant reduction of IkBα with epoxomicin or ALLN ( Fig 2D) . Proteasome inhibitors induce NF-kB nuclear translocation, DNA binding, transcriptional activity, and phosphorylation of p65 on serine 536. The results described above stimulated us to investigate whether the reduction of IkBα resulted in an activation of NF-kB transcriptional activity. To address this point, we used different experimental approaches. We carried out a transcriptional activity assay of NF-kB by luciferase reporter assay. Cells were transfected with NFkB-dependent luciferase reporter construct and treated with the indicated doses of proteasome inhibitors for 14-16 hours. IK cells treated with 10 or 25 nM bortezomib displayed a marked increase on the basal luciferase activity (Fig 3A) . Such increase was also observed when IK cells were treated with MG-132, epoxomicin or ALLN. Consistent with this result, we also observed that treatment with MG-132 or bortezomib resulted in the formation of a DNA/NF-kB complex as assessed by EMSA ( Fig  3B) . This complex showed similar pattern of migration to that observed with TNF. To provide a control of proteasome inhibitors action, we stimulated a melanoma cell line (M16) and the endometrial carcinoma cell lines RL-95 with TNF. TNF treatment triggers the canonical, proteasome-depdendent, IkBα degradation and p65 NF-kB binding activity in both cell lines. As expected, both bortezomib and MG-132, reduce NF-kB binding to DNA in M16 cells. Similar results are obtained in RL cells with MG-132 (Fig 3C) . A supershift analysis using a p65 antibody caused a marked reduction on the NF-kB complex and the appearance of a supershifted band in both MG and TNF stimulated cells (Fig 3B) . Accordingly, western blot analysis on nuclear and cytoplasmic extracts revealed that treatment with either MG-132 or bortezomib induced p65 nuclear translocation on IK cells. As control we treated HEC cells with TNF, which is known to induce p65 nuclear translocation (Fig 3C) . Finally, we also analyzed phosphorylation of p65 subunit of NF-kB on serine 536, which has been associated with increased transactivation potential. Treatment with bortezomib or other proteasome inhibitors resulted in increased phosphorylation on serine 536 of p65 in all the cell lines that were tested (Fig 3D) SR-IkBα-blocks proteasome inhibitor-induced NF-kB activity. To ascertain whether IkBα degradation was dependent on serine phosphorylation, we transfected IK and HEC cells with a construct encoding a form of IkBα carrying serine-toalanine mutations at residues 32 and 36, named SR-IkBα. These mutations prevent IkBα phosphorylation and its subsequent proteasomemediated degradation, thereby preventing release and nuclear translocation of NF-kB (Rodriguez et al., 1996) . Expression of SR-IkBα caused a marked reduction on the activation of NF-kB transcriptional activity by either bortezomib or MG-132 in HEC and IK cells (Fig 4) . This data supports the hypothesis that proteasome inhibitors require phosphorylation and degradation of IkBα. NF-kB activity induced by proteasome inhibitors requires functional IKKα and IKKβ. The major upstream kinases involved in NF-kB activation are IKKα and IKKβ. We investigated whether these kinases were involved in activation of NF-kB by proteasome inhibitors. Treatment of IK, HEC or RL cells with bortezomib caused increased phosphorylation of IKKα/β, as assessed by western blot analysis of lysates with an antibody that specifically recognizes the phosphorylated forms of both proteins (Fig 5A) . To determine the requirement of either or both IKKα or IKKβ subunits, we co-transfected IK or HEC cells with NF-kB-luciferase reporter construct plus dominant negative forms of either IKKα (DΝ−IKKα) or IKKβ (DN-IKKβ). Both DN-IKKα and DN-IKKβ blocked NF-kB transcriptional activity on IK cells treated with 25 nM of bortezomib (Fig 5B, left) and in IK and HEC cells treated with MG132 (Fig5B, right). To further demonstrate the role of IKKα or IKKβ subunits, we designed lentiviral shRNAs targeting each subunit, to knock-down endogenous expression. We designed shRNAs targeting two sequences for each kinase. Infection of IK cells with lentiviruses carrying shRNAs to either IKKα or IKKβ subunits revealed that each shRNA selectively knockeddown the expression of the corresponding protein ( Fig 5C) . These two shRNAs were selected for subsequent experiments. We infected IK cells with the functional IKKα or IKKβ shRNAs for 3 days to allow protein knock-down; and cells were subsequently treated with bortezomib. As shown in figure 5D , both IKKα shRNA, and IKKβ shRNA blocked NF-kB activity with similar efficiency to the dominant negative forms. Our data suggest that phosphorylation and expression of both IKKα and IKKβ subunits are required for proteasome inhibitor-induced NF-kB activity. Neither IKKα nor IKKβ knock down increased the cell viability in proteasome inhibitor treated cells (data not shown). (Fig 6A) . As shown in figure 6 , both IKKα and IKKβ shRNA strongly inhibited p65 phosphorylation. The cells transfected with IKKβ shRNA showed a reduction of phosphorylated IkBα, but also a decrease on total IkBα protein. However, the molecular weight shift on migration of IkBα and degradation of IkBα by bortezomib remained unaffected (Fig 6A) . Our findings suggest that p65 phosphorylation is mediated by either IKKα or IKKβ, but also show that IkBα degradation is independent of IKKs. Similar results were obtained with IK cells (data not shown). These results suggest that proteasome inhibitors increase NF-kB activity, by involving the p65 subunit of NF-kB. To determine if transcriptional activity of NF-kB was really dependent of p65 subunit, we co-transfected p65 siRNA or c-Rel siRNA with the NF-kB reporter construct, and cells were exposed to bortezomib. Transfection of p65 siRNA resulted in a significant decrease of NF-kB transcriptional activity in both IK and HEC cells (Fig 6B) . Such result was not observed when c-Rel siRNA was transfected. Proteasome inhibitors induce cell death and activate NF-kB in primary culture explants from endometrial adenocarcinoma samples. To further demonstrate the effect of proteasome inhibitors on endometrial carcinoma, we assessed the effects of such inhibitors on primary explants obtained from human endometrial carcinomas. After enzymatic digestion, glandular-like structures were plated on 24-well dishes and the epithelial origin of the samples was assessed by immunofluorescence to a wide spectrum cytokeratin, cytokeratin-7 and β-catenin, two proteins that are only expressed on endometrial cells of epithelial origin, but not on stromal cells (Fig 7A) . To ascertain whether proteasome inhibitors induced apoptosis on primary explants as well as on cell lines, we treated endometrial explant cultures with 0,5 μM MG-132 or 25 nM bortezomib and we assessed caspase-3 activation by immunofluorescence with an antibody that recognizes its active form (Fig 7B) . Both MG-132 and bortezomib increased the number of cytokeratin positive cells displaying active caspase-3. These results suggest that bortezomib and MG-132 induce apoptotic cell death on primary endometrial carcinoma explants. To determine whether MG-132 and bortezomib also were able to activate NF-kB, we analysed IkBα phosphorylation and degradation after treatment with these two inhibitors at doses that induced IkBα degradation and phosphorylation on endometrial carcinoma cell lines. As shown in figure 7C , both MG-132 and bortezomib induced phosphorylation and degradation of IkBα and phosphorylation of p65 at serine 536 in a similar way to that observed in all cell lines tested.
IKKα and IKKβ
Altogether, these results demonstrate that proteasome-inhibitors are able to activate NF-kB signalling in primary endometrial carcinoma explants.
DISCUSSION
Bortezomib and other proteasome inhibitors trigger cell growth arrest or apoptosis on several tumours (2). Bortezomib is a modified dipeptidyl boronic acid that creates compounds that form covalent complexes with the proteasome. It is used as a chemotherapeutic agent for treatment of relapsed and refractory multiple myeloma (3, 4, 5, 6, 7) . It is also a promising anti-cancer agent for treatment of solid tumours. In many different types of tumour cells, proteasome inhibition cause cell death by blocking NF-kB activity. In this article, we demonstrate for the first time, that bortezomib and other three proteasome inhibitors (MG-132, Epoxomicin and ALLN) may induce apoptosis in endometrial cancer cell lines and primary culture explants from endometrial carcinomas. Cell death was accompanied by activation of caspases and apoptotic nuclear morphology. However, in contrast to that observed on other cancer cells, this cell death is not related with NF-kB blockage. In endometrial cancer cells, bortezomib and other proteasome inhibitors increase NF-kB activity rather than its inhibition. NF-kB is a family of transcription factors, involved in the regulation of genes encoding cytokines, cytokine receptors, and cell adhesion molecules, that drive immune and inflammatory responses (14, 15, 16 ). However, NF-κB is also related to carcinogenesis, by regulating genes involved in apoptosis, the cell cycle, differentiation, invasion and cell migration (16, 19) . Therefore, inhibition of NFkB is a promising target for treatment of cancer. Because of their ability to block IkBα degradation, proteasome inhibitors have been widely used as inhibitors of NF-kB. In fact, inhibition of NF-kB activity has been reported as the main mediator of cytotoxic effects of bortezomib. One of the main goals of this study was to investigate the effect of proteasome inhibition on NF-kB in endometrial carcinoma. Treatment of endometrial carcinoma cell lines with bortezomib did not stabilize or inhibit IkBα, but induced phosphorylation and reduction of IkBα levels. Similar results were obtained when the endometrial adenocarcinoma cell lines were exposed to the other three proteasome inhibitors (MG-132, epoxomicin or ALLN) which inhibit the proteasome by other chemical mechanisms. Although these results seem to contradict the well-established mechanism of IkBα degradation by proteasome inhibition, it is worth mentioning that some recent evidences suggest that proteasome inhibitors may activate NF-kB in some cancer cell lines. This was the case of the colon adenocarcinoma cell line HT-29 after treatment with MG-132 (25) . In agreement with this report, we have found IkBα degradation, IKK phosphorylation and increased transcriptional activity of NF-kB, as a result of exposure to the four different proteasome inhibitors. Phosphorylation and degradation of IkBα is followed by increase of NF-kB activity. We found that proteasome inhibitors induced the formation of a DNA/NF-kB complex displaying similar migration properties than the observed after stimulation with TNF. TNF is a well-known activator of the canonical NF-kB pathway which results in nuclear translocation of p65 subunits. Therefore, this result suggests that p65 may be involved in NF-kB activity induced by such inhibitors. Accordingly, we have found supershift of the NF-kB complex using p65 antibody, nuclear translocation of p65 and, more importantly, p65 siRNA reduced the transcriptional activity induced by proteasome inhibitors. Moreover, we have found that all proteasome inhibitors tested, including bortezomib increase p65 phosphorylation on serine 536. Recent evidences suggest that phosphorylation on this serine is critical for p65 transcriptional activity after different stimuli such as lymphotoxin beta (21) (20, 24) . In this study, we have found that shRNA inhibition of either IKKα and IKKβ blocked p65 at serine 536 and NF-kB transcriptional activity, suggesting a major role for p65 subunit in proteasome inhibitor-induced activation. Consistent with this hypothesis, we have found p65 nuclear translocation and reduced NF-kB transcriptional activity in p65 siRNA transfected cells, indicating a main role for p65 in NF-kB activation. As discussed above, IkBα is degraded even after IKK knock-down by shRNA, but both serine phosphorylation of p65 and NF-kB transcriptional activity is inhibited. Altogether the mechanism by which proteasome inhibitors induce NF-kB activity seems to be tightly regulated. Such activation requires phosphorylation and degradation of IkBα but also an IKK-mediated phosphorylation of p65. Despite the activation of NF-kB, proteasome inhibitors are able to induce cytotoxic effects on endometrial carcinoma cell lines. Although it may be surprising, these features are also observed after treatment of cancer cells with other stress signals such as ionizing radiation, hypoxia or ultraviolet light and chemotherapeutic drugs such as vincristine, vinblastine, etoposide, adryamicin, cisplatin, daunorubicin, etc (31) . For example, topoisomerase inhibitors such as camptothecin or doxorubicin activate NF-kB but induce cell death (32, 33, 34) . However, the NF-kB activation observed after proteasome inhibitors treatment has a particular relevance because they are widely used as pharmacological blockers of IkBα degradation and subsequent NF-kB inhibition. In fact, as a control of correct proteasome inhibition, we have found that such inhibitors are effective to block NF-kB activation by TNF in both a melanoma cell line and the RL-95 endometrial cell lines, indicating that such drugs are inhibiting preoteasome and, as a consequence, the NF-kB activation by the canonical pathway. These results indicate that proteasome inhibitors are effective to block NF-kB by TNF, but long treatment (hours) lead to induction of NF-kB by themselves NF-kB inhibition has been proposed as the main mechanism by which proteasome inhibitors are used as anticancer-drugs. Although in some cell types NF-kB activation trigger cell death (Farhana et al, Jin et al.,) , NF-kB does not mediates cytotoxic effects of proteasome inhibition. To test this hypothesis endometrial cancer cell lines were infected with lentiviruses carrying shRNA either to IKKα or IKKβ and treated with cytotoxic doses of bortezomib or MG-132 and we assessed cell viability by MTT assay. Neither IKKα nor IKKβ shRNA increased cell viability after treatment with such inhibitors (supplementary Figure 1) . Rather, we observed a slightly decrease. We observed that IKKα or IKKβ knock-down reduced basal proliferation and viability of endometrial cancer cells (data not shown), which is consistent with an anti-apoptotic role of NF-kB in endometrial carcinoma cell lines.
Because of the use of bortezomib on treatment of multiple myeloma and the promising effects on some solid tumours we decided to test the ability of this inhibitor to induce apoptosis on primary explants from tumour samples from patients with endometrial carcinoma. Both MG-132 and bortezomib, induced activation of caspase-3, suggesting that both inhibitors triggered apoptotic cell death. Similar to that observed on endometrial cancer cell lines, bortezomib and MG-132 caused IkBα phosphorylation and degradation which suggests that such inhibitors also activate NF-kB on primary endometrial carcinoma explants. During the last years, other molecular mechanisms, not related to NF-kB have been involved in proteasome inhibitor cell death. Among them, it has been reported an involvement of the endoplasmic reticulum stress (ER stress) (37, 38, 39) proteins or increases in expression of death receptors (40) . Other recent findings suggest that proteasome inhibitors may induce apoptosis by up-regulating BH3 only family members such as NOXA (41, 42, 43) , Bik (44, 45) or PUMA (46) . To determine whether proteasome inhibitors produce ER stress in endometrial cancer cells we have performed RT-PCR analysis of GADD153 and heme-oxygenase, two stress genes that have been previously demonstrated to increase after ER stress after bortezomib treatment (37, 38, 39) . We have alsoanalysed NOXA, BIK and Puma expression after treatment with bortezomib. (Supplementary Figure 2) . In agreement with previous reports, we have found upregulation of both GADD153 and hemeoxygenase, suggesting that ER stress may be involved in apoptosis triggered by proteasome inhibitors.We have not found significant changes in either Puma or Noxa, but a slightly and transient increase in Bik levels. Future experiments will determine whether BH3 only proteins such as Bik and ER stress regulate apoptosis induced by proteasome in endometrial carcinomas.
In summary, we have demonstrated that bortezomib and other three proteasome inhibitors induce cell death in four endometrial carcinoma cell lines as well as in primary culture explants obtained from endometrial carcinoma samples.
However, all proteasome inhibitors tested activated NF-kB, a signalling pathway strongly associated in oncogenesis in many types of cancer. Our findings may have important biochemical and clinical relevance. First, because proteasome inhibitors are widely used as pharmacological inhibitors of NF-kB on the basis of their ability to block IkBα degradation but, as we show here for endometrial carcinomas, they can rather lead to activation of NF-kB. Therefore, the general use of such inhibitors as NF-kB blockers has to be carefully analysed for particular cell types. Second, if proteasome inhibitors may activate of NF-kB, administration of these drugs may increase the expression of genes involved with proliferation, apoptosis resistance or angiogenesis. The activation of these genes could explain the development of adverse effects in patients under treatment with proteasome inhibitors. Additional studies should be performed to demonstrate that the NF-kB activation shown in this report in endometrial carcinoma cell lines, and in a previous study on colonic adenocarcinoma cell lines, is also taking place in other types of tumour cells. A, endometrial carcinoma explants after 3 days in culture stained with antibodies against pancytokeratin, cytokeratin-7 or β-catenin. Nuclei were visualized by Hoechst staining.. B, endometrial carcinoma explants were treated with bortezomib 25 nM, MG-132 0,5 mM or left untreated for 24 hours, fixed and stained with anti-active caspase-3 antibody (green), citokeratin-7 (red) and hoechst dye to visualize nuclei (blue).C, Two different endometrial carcinoma explants were treated with 25 nM bortezomib or 0,5 μM MG-132 and cell lysates were analyzed by western blot by ΙκΒα, phosphorylate IkBα, phosphorylated p65 or tubulin. 
